Is OCS or OKUR more undervalued in 2026?

CirclFi compares Oculis Holding AG (OCS) and OnKure Therapeutics, Inc. (OKUR) using 13 institutional-grade valuation models. OCS has a Quality of Company score of 3.8/10 while OKUR scores 5.6/10.

Which is a better buy — OCS or OKUR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do OCS and OKUR valuations compare?

OCS at $29.65 and OKUR at $4.12 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

OCS vs OKUR Valuation Comparison 2026 — Intrinsic Value Analysis

OCS

Biotechnology

Oculis Holding AG

Quality

3.8

out of 10

Value Trap

SAFE

Price

$29.65

Last close

Models

8/13

Active

OKUR

Biotechnology

OnKure Therapeutics, Inc.

Quality

5.6

out of 10

Value Trap

LOW

Price

$4.12

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	OCS Fair Value	OCS Upside	OKUR Fair Value	OKUR Upside
Bayesian DCF	Intrinsic	$8.55	-71.2%	$3.04	-26.2%
Earnings Power Value	Intrinsic	—	—	$7.86	+66.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.25	-92.4%	$6.37	+54.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for OCS vs OKUR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OCS vs OKUR — Which Stock Is More Undervalued?

OKUR scores higher with a 5.6/10 quality rating vs OCS's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Oculis Holding AG (OCS) and OnKure Therapeutics, Inc. (OKUR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OCS currently trades at $29.65 with a QOC of 3.8/10, while OKUR trades at $4.12 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).